+

WO1995018629A1 - Procede de traitement et de prevention des maladies chez des animaux - Google Patents

Procede de traitement et de prevention des maladies chez des animaux Download PDF

Info

Publication number
WO1995018629A1
WO1995018629A1 PCT/US1994/014839 US9414839W WO9518629A1 WO 1995018629 A1 WO1995018629 A1 WO 1995018629A1 US 9414839 W US9414839 W US 9414839W WO 9518629 A1 WO9518629 A1 WO 9518629A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
animal
melatonin
effective amount
increased
Prior art date
Application number
PCT/US1994/014839
Other languages
English (en)
Inventor
David J. Olsen
Original Assignee
Biomedtech Engineering, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedtech Engineering, Inc. filed Critical Biomedtech Engineering, Inc.
Priority to AU15542/95A priority Critical patent/AU1554295A/en
Publication of WO1995018629A1 publication Critical patent/WO1995018629A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Aggression treatment or altering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédés destinés à augmenter la quantité efficace d'hormone de croissance chez un animal en vue de stimuler le système immunitaire dudit animal pendant la phase précoce du sommeil nocturne. Lesdits procédés entraînent le renforcement du système immunitaire de l'animal traité.
PCT/US1994/014839 1994-01-05 1994-12-29 Procede de traitement et de prevention des maladies chez des animaux WO1995018629A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15542/95A AU1554295A (en) 1994-01-05 1994-12-29 Method for treatment and prevention of disease in animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17766694A 1994-01-05 1994-01-05
US08/177,666 1994-01-05

Publications (1)

Publication Number Publication Date
WO1995018629A1 true WO1995018629A1 (fr) 1995-07-13

Family

ID=22649485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/014839 WO1995018629A1 (fr) 1994-01-05 1994-12-29 Procede de traitement et de prevention des maladies chez des animaux

Country Status (2)

Country Link
AU (1) AU1554295A (fr)
WO (1) WO1995018629A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067719A3 (fr) * 2003-01-28 2005-03-31 Advisys Inc Reduction de reforme dans l'hormone de liberation de l'hormone de croissance (ghrh) d'animaux de troupeau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837202A (en) * 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837202A (en) * 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACTA ENDOCRINOLOGICA (COPENH), Volume 123, issued 1990, P. FRANCO et al., "Influence of Growth Hormone on the Immunosuppressive Effect of Prednisolone in Mice", pages 339-344. *
BIOCHEMICAL PHARMACOLOGY, Volume 38, Number 5, issued 01 March 1989, K. KELLEY, "Growth Hormone, Lymphocytes and Marcrophages", pages 705-713. *
CLIN. EXP. IMMUNOL., Volume 68, issued 1987, B. LAWLER GOFF et al., "Growth Hormone Treatment Stimulates Thymulin Production in Aged Dogs", pages 580-587. *
PROGRESS IN NEUROENDOCRINIMMUNOLOGY, Volume 3, Number 4, issued 1990, D. WEIGENT et al., "Growth Hormone and the Immune System", pages 231-241. *
SCIENCE, Volume 239, issued 12 February 1988, C. EDWARDS et al., "A Newly Defined Property of Somatotropin: Priming of Macrophages for Production of Superoxide Anion", pages 769-771. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067719A3 (fr) * 2003-01-28 2005-03-31 Advisys Inc Reduction de reforme dans l'hormone de liberation de l'hormone de croissance (ghrh) d'animaux de troupeau

Also Published As

Publication number Publication date
AU1554295A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
EP0518468B1 (fr) Compositions à base de mélatonine
RU2141844C1 (ru) Фармацевтическое соединение
Astrup et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
Morley et al. Stress induced eating
Davis et al. Cachexia and anorexia: cancer's covert killer
US4687763A (en) Composition and method for increasing levels or release of brain serotonin
Tolosa et al. Apomorphine in Huntington's chorea: clinical observations and theoretical considerations
US8728511B2 (en) Method of treatment comprising administering controlled release melatonin
JPH10502644A (ja) 免疫機能の調整方法
CA2260892A1 (fr) Coupe-faim
US4639465A (en) Method and composition for relieving pain
CA2267381A1 (fr) Methode de traitement de troubles neurologiques ou neuropsychiatriques
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
Robertson et al. Case study: the use of melatonin in a boy with refractory bipolar disorder
US20010044469A1 (en) Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法
Gregor et al. The role of gut-glucagon-like immunoreactants in the control of gastrointestinal epithelial cell renewal
CZ155494A3 (en) The use of dopamine and prolactin stimulator antagonist for preparing a pharmaceutical preparation and the pharmaceutical preparation itself
WO1995018629A1 (fr) Procede de traitement et de prevention des maladies chez des animaux
US4388325A (en) L-Arginine D,L-pyroglutamate as a pharmaceutical agent having an activity at the neuro-endocrinal level
US5650438A (en) Process for activating reproduction in seasonal breeding animals by administering L-dihydroxyphenylalanine (L-dopa)
Maksimovich Structure and function of the vertebrate pineal gland
US4650668A (en) Composition for relieving toothache pain and other forms of intense pain
FR2574295A1 (fr) Medicaments a base de gluconate de zinc utiles pour le traitement des hyperprolactinemies
Pounder Degrees of acid suppression and ulcer healing: dosage considerations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载